Global ETD Search

11	Preclinical exploration of novel small molecules as anticancer agents in triple-negative and HER2/neu-positive breast cancers Weng, Shu-Chuan January 2008 (has links) No description available. Biomedical Research Cellular Biology Pharmacology breast cancer HER2/neu triple-negative breast cancer tamoxifen estrogen receptor HDAC Akt PDK-1 hsp90 fluorescent polarization autophagy LAMP-2 LAMP-1 apoptosis celecoxib SAHA MS-275 Confocal microscope
12	Ex vivo reprogramming of tumor-reactive immune cells from FVBN202 mice bearing lung metastatic mammary carcinoma: an immunotherapeutic opportunity revealed against recurrence Hall, Charles 23 July 2013 (has links) Metastatic breast cancer treatment has seen few advances in recent years, yet treatment resistance continues to rise, causing disease recurrence. A pilot study was performed to determine the efficacy of ex vivo expansion and reprogramming of tumor-reactive immune cells from experimental metastatic tumor-sensitized mice. Also, phenotypic changes in tumors due to metastasis or tumor microenvironment influences were characterized. Metastatic neu+ mouse mammary carcinoma (mMMC) and its distant relapsing neu-antigen-negative variant (mANV) were investigated in FVBN202 mice. Tumor-reactive central memory CD8+ T cells and activated NK/NKT cells were successfully reprogrammed and expanded during 6-day expansion from mMMC- and/or mANV-sensitized mice, resulting in tumor-specific cytotoxicity. mMMC exhibited a flexible neu-expression pattern and acquired stem-like, tumorigenic phenotype following metastasis while mANV remained stable except decreased tumorigenicity. Myeloid-derived suppressor cell (MDSC) levels were not increased. Adoptive cellular therapy (ACT) with reprogrammed tumor-reactive immune cells may prove effective prophylaxis against metastatic or recurrent breast cancer. Metastatic breast cancer Immunotherapy Her2/neu IFN-γ CD44+CD24-/low stem-like phenotype Tumorigenicity Mouse mammary carcinoma Invasion Common gamma-chain cytokines Central memory T cells Natural Killer cells Natural Killer T cells Tumor Microenvironment Tumor-specific cytotoxicity Prophylactic adoptive cellular therapy Medicine and Health Sciences

Search results

Preclinical exploration of novel small molecules as anticancer agents in triple-negative and HER2/neu-positive breast cancers

Ex vivo reprogramming of tumor-reactive immune cells from FVBN202 mice bearing lung metastatic mammary carcinoma: an immunotherapeutic opportunity revealed against recurrence